Biocon Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Shreehas Tambe
Chief Executive Officer (CEO)
n/a
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | less than a year |
| Participación del CEO | n/a |
| Permanencia media de la dirección | less than a year |
| Promedio de permanencia en la Junta Directiva | 4.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Actualización de narrativa • Jun 15
BIOCON: Future Margin Reset Will Support Biosimilars Expansion And Leadership Transition
Narrative Update Analysts have trimmed Biocon's fair value estimate to ₹506.0 from ₹544.20 as they reset expectations around profit margin assumptions and a higher future P/E, while also fine tuning discount rate and revenue growth inputs. Analyst Commentary Recent Street commentary around related life sciences companies highlights how bullish analysts think about valuation resets, margin potential and recovery timelines.
Actualización de narrativa • Jun 01
BIOCON: Tough Macro And Execution Risks Will Restrict Future P/E Upside
Analysts have nudged their fair value estimate for Biocon slightly higher to about ₹299 from roughly ₹296, reflecting updated assumptions for discount rate, revenue growth, profit margins and future P/E multiples. The rationale is informed by recent Street research on peer companies that highlights the impact of tougher macro conditions, underappreciated balance sheet items and potential margin improvements under refreshed management teams.Artículo de análisis • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Actualización de narrativa • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.Actualización de narrativa • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Actualización de narrativa • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.Actualización de narrativa • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Actualización de narrativa • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Actualización de narrativa • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Actualización de narrativa • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Actualización de narrativa • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Actualización de narrativa • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Actualización de narrativa • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Artículo de análisis • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Actualización de narrativa • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Artículo de análisis • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Actualización de narrativa • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Artículo de análisis • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Actualización de narrativa • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Actualización de narrativa • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Artículo de análisis • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...Artículo de análisis • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Artículo de análisis • Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now
Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...
Nueva narrativa • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.CEO
Shreehas Tambe (52 yo)
less than a year
Permanencia
₹8,133,384
Compensación
Mr. Shreehas Pradeep Tambe, MTech, is CEO, MD & Additional Director of Biocon Limited from April 1, 2026. He has been Managing Director and Chief Executive Officer of Biocon Biologics Limited since Decembe...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Executive Chairperson | 47.6yrs | ₹42.28m | 29.94% ₹ 201.3b | |
| CEO, MD & Additional Director | less than a year | ₹8.13m | sin datos | |
| Chief Financial Officer | less than a year | sin datos | sin datos | |
| Chief Technology Officer | less than a year | sin datos | sin datos | |
| Head of Investor Relations | 3.8yrs | sin datos | sin datos | |
| Company Secretary & Compliance Officer | less than a year | sin datos | sin datos | |
| SVP & Global Head Corporate Communications & Corporate Brand Biocon Group | no data | sin datos | sin datos | |
| Chief Human Resources Officer | less than a year | sin datos | sin datos | |
| Chief Development Officer | less than a year | ₹2.53m | sin datos | |
| Chief Commercial Officer | no data | sin datos | sin datos | |
| Head of Governance | less than a year | sin datos | sin datos | |
| Chief Commercial Officer of Advanced Markets - Biocon Biologics | 4.4yrs | sin datos | sin datos |
0.2yrs
Permanencia media
56.5yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de BIOCON no se considera experimentado ( 0.2 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Founder & Executive Chairperson | 47.6yrs | ₹42.28m | 29.94% ₹ 201.3b | |
| CEO, MD & Additional Director | less than a year | ₹8.13m | sin datos | |
| Non-Executive Non-Independent Director | 25.8yrs | ₹6.80m | 0.33% ₹ 2.2b | |
| Independent Non-Executive Director | 7.9yrs | ₹8.33m | sin datos | |
| Lead Independent Director | 4.2yrs | ₹6.80m | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive and Independent Director | 2.8yrs | ₹7.56m | sin datos | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive and Independent Director | 2.9yrs | ₹6.63m | sin datos | |
| Non-Executive Director | 4.6yrs | ₹5.95m | 0.20% ₹ 1.3b | |
| Member of Scientific Advisory Board | no data | sin datos | sin datos | |
| Non-Executive and Independent Director | 2.1yrs | ₹6.63m | sin datos |
4.2yrs
Permanencia media
67yo
Promedio de edad
Junta con experiencia: La junta directiva de BIOCON se considera experimentada (4.2 años de antigüedad promedio).
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/20 16:39 |
| Precio de las acciones al final del día | 2026/06/19 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2026/03/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también contamos con guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Biocon Limited está cubierta por 39 analistas. 18 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |